712 North

9:00 AM - 9:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
712 North is developing personalized mitochondrial medicines to treat a spectrum of diseases either triggered by, or affecting mitochondrial dysfunction.

We aim to accelerate the development of treatments for Alzheimer's and cancer by initially targeting well defined orphan genetic diseases in order to quickly provide mechanism-based proof of concept and drug safety/pharmacokinetics data in small and homogeneous patient cohorts.

Next, we will leverage this data to achieve quick approval for the initial indication, then use the proof of mechanism and safety data to accelerate trials in the target Alzheimer's population.

In the meantime, we are exploring other blockbuster market sized indication for potential targeting of our developed drugs.

To maintain capital efficiency, we are aiming to move our initial programs forward with a maximum ratio of non-dilutive funding.

712 North features Dr. Charles Craik, Dr. Frank McCormick and Dr. Michelle Arkin on its Board of Advisors
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Various initial hits
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):